Oxycodone News and Research

RSS

Research roundup: Palliative care and ACOs; employers and Supreme Court case on contraception

In preparation for the new ACO environment, leaders recognized the contribution palliative care can make to health care "value," especially in the care of our sickest (and most expensive) patients ...

24 Feb 2014

Study reveals that more than 14% of pregnant women are prescribed opioids for pain

More than 14 percent of pregnant women were prescribed opioids (narcotics) for pain at some time during their pregnancy, according to a study posted to the online version of Anesthesiology.

13 Feb 2014

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.

24 Jan 2014

Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists at Ume- University in Sweden have been able to trace narcotics substances and prescription drugs in measurements of wastewater from 33 Swedish sewage treatment plants. Cocaine, amphetamine, and methamphetamine, in measurable concentrations, were found in a total of half of the locations.

17 Dec 2013

Scientists investigate factors that influence choice of abused drugs

Prescription opioid abuse has reached epidemic levels in the past 15 years. Scientists investigating why people favor one drug over another have found that oxycodone and hydrocodone are the drugs of choice for 75% of opioid-dependent individuals.

3 Dec 2013

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain.

27 Nov 2013

QRxPharma refiles MOXDUO New Drug Application with US FDA

QRxPharma Limited announced today that the Company resubmitted its MOXDUO New Drug Application. At a meeting in early October, the United States Food and Drug Administration provided QRxPharma with guidance on its requirements for the NDA refiling as well as data validation documentation.

26 Nov 2013

Over 50% of nonsurgical patients prescribed opioids during hospitalizations, analysis finds

Amid a growing climate of concern regarding the overuse of opioid pain medications, a comprehensive analysis of more than 1 million hospital admissions has found that over 50 percent of all nonsurgical patients were prescribed opioids during their hospitalizations -- often at very high doses -- and that more than half of those exposed were still receiving these medications on the day they were discharged from the hospital.

14 Nov 2013

Access to health care increases prescription opioid abuse

Researchers at Indiana University-Purdue University Indianapolis say one way to gauge the extent of prescription opioid pain reliever abuse in any Indiana county is to count the number of health care providers, particularly dentists and pharmacists.

5 Nov 2013

New study reveals striking data about misuse of painkillers and sedatives by teens, young adults

With prescription drug abuse at epidemic levels nationwide, and overdoses killing more people than auto accidents in many states, a new University of Michigan study provides striking new data about the misuse of potent prescription painkillers and sedatives by teens and young adults.

30 Oct 2013

Pfizer to continue development of Remoxy Extended-Release Capsules CII

Pfizer Inc. announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy (oxycodone) Extended-Release Capsules CII.

22 Oct 2013

Breast cancer patients receiving nerve block with general anesthesia have less cancer recurrence

Breast cancer patients who received the combination of a nerve block with general anesthesia for their breast cancer surgery had less cancer recurrence and were three times less likely to die than those who received only general anesthesia, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

16 Oct 2013

MNK-795 for acute pain management: an interview with Dr Lynn Webster

MNK-795 is a product in development that is intended to be used for acute pain. It has some unique properties. First, it is an extended release formulation, meaning that it’s going to last more than three to four hours. It was studied to be dosed once every 12 hours, and that is unique for an acute pain formulation.

8 Oct 2013

Metabolic enzymes in opium poppy are used to produce valuable painkilling drugs

University of Calgary scientists have discovered metabolic enzymes in the opium poppy that play "widespread roles" in enabling the plant to make painkilling morphine and codeine, and other important compounds.

5 Oct 2013

Study assess use of prescription painkillers for chronic pain among patients pre- and post-obesity surgery

Chronic use of prescription painkillers, also known as opioids, among obese patients prior to bariatric surgery continues after surgery, according to a new Kaiser Permanente study published today in the Journal of the American Medical Association.

2 Oct 2013

Research roundup: Managed care for dementia patients; bundled payments after the hospital; disparities among Medicare beneficiaries

Dementia is a leading cause of death in the United States; however, patients dying with this disease may not receive optimal end-of-life care. ... many of these [nursing home] residents commonly experience burdensome and costly interventions, such as hospital transfers, tube-feeding, and intravenous antibiotics. ... Nursing home reimbursement policies are among the factors that incentivize more aggressive care. ... This study linked unique prospective clinical data with Medicare claims to describe and compare patterns of care between nursing home residents with advanced dementia enrolled in a Medicare managed-care insurance plan and those with fee-for-service Medicare.

30 Sep 2013

FDA takes steps to restrict the use of pain meds

The Food and Drug Administration will require a class-wide label change for long-acting opioids aimed at limiting use of these drugs to patients with severe, refractory pain.

12 Sep 2013

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Mallinckrodt announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

29 Aug 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.